Results 251 to 260 of about 14,066,519 (402)

P-1172. Characterization of Clinical Pathogens and Microbiological Outcomes for Patients Treated with IV Fosfomycin (IV-FOS) in the ZEUS Phase 2/3 Complicated Urinary Tract Infection, including Acute Pyelonephritis (cUTI/AP) Trial [PDF]

Hainv Gao, Mauricio Rodriguez, Surya Chitra, Judith N Steenbergen   +3 more
openalex   +1 more source

Blinded Sample Size Re-estimation in Comparative Clinical Trials With Overdispersed Count Data: Incorporation of Misspecification of the Variance Function

, 2020
Masataka Igeta, Shigeyuki Matsui
openalex   +1 more source

LSD1/KDM1A inhibitors in clinical trials: advances and prospects [PDF]

, 2019
Yuan Fang, Guochao Liao, Bin Yu
openalex   +1 more source

Meta-analysis in clinical trials revisited.

Contemporary Clinical Trials, 2015
R. Dersimonian, N. Laird
semanticscholar   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Significance, Fragility, and Robustness in Clinical Trials: Stratifying Statistical Evidence. [PDF]

Cureus
Heston TF.
europepmc   +1 more source

Antimicrobial Resistance (AMR) Trials: Clinical Trials are Essential for Testing New Approaches to Combat the Rise of AMR

Dhavalkumar Gohel*
openalex   +1 more source

Metabolic Reprogramming of Endothelial-Related Pathways in COVID-19 Patients Treated with Hyperbaric Oxygen Therapy: A Randomized Clinical Trial [PDF]

Natalia Jermakow, Klaudia Brodaczewska, Kot Jacek, Krzysztof Urbanowicz, Jacek Turyn, Ryszard T. Smoleński, Arkadiusz Lubas, Krzysztof Kłos, Jacek Siewiera   +8 more
openalex   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Participation in U.S.-Based ALS Clinical Trials by Sex and Race. [PDF]

Muscle Nerve
Levine MP, Chung SY, Quigg KH, Carey J, Babu S, Paganoni S, Berry JD.   +6 more
europepmc   +1 more source